Home > Boards > US OTC > Biotechs > Response Genetics Inc. (RGDXQ)

#2, $RGDXQ Asset Value: $0.361 per share. Response

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
mick Member Profile
Member Level 
Followed By 2,741
Posts 883,427
Boards Moderated 328
Alias Born 09/04/00
160x600 placeholder
mick Member Level  Wednesday, 09/09/20 05:17:46 PM
Re: mick post# 2801
Post # of 2827 
#2, $RGDXQ Asset Value: $0.361 per share. Response develops, manufactures and markets rapid onsite diagnostic tests for use
with its RAMP platform for clinical, biodefense and environmental applications.

RAMP represents a unique paradigm in diagnostics that provides reliable, quality results in minutes.

https://investorshub.advfn.com/Response-Genetics-Inc-RGDXQ-9727/

The RAMP platform consists of a reader and single use disposable test cartridges and has the potential
to be adapted to any other medical
and nonmedical immunoassay based test currently performed in laboratories.

Response clinical tests are commercially available for the aid in early detection of heart attack,
congestive heart failure, thromboembolism and infectious diseases.

In the nonclinical market, RAMP tests are currently available for
the environmental detection of
West Nile Virus antigen and for Biodefense applications including
the rapid onsite detection of anthrax, smallpox, ricin and botulinum toxin.


Website: http://www.responsegenetics.com
Phone: (323) 224-3900
Email: ir@responsegenetics.com

ON GOING BUYOUT BY~~~~~>~(CGIX)~ Cancer Genetics, Inc.





Latest News
JUN 1, 2020
Cancer Genetics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Strategic Business Updates
https://www.cancergenetics.com/

Business Description;

We are a diagnostics company focused on developing and commercializing proprietary
genomic tests and services to improve the diagnosis,
prognosis and response to treatment of cancer (theranosis).

Our proprietary tests target cancers where prognosis information
is critical and where predicting treatment outcomes using currently available techniques is limited.

These cancers include ematological, urogenital and HPV-associated cancers.

We have commercially launched MatBA -CLL and -SLL, our first
proprietary microarray diagnostic tests, and seek to provide our
tests and services to oncologists and pathologists at hospitals,
cancer centers and physician offices,
as well as to biopharmaceutical companies and clinical research organizations for their clinical trials.


Website: http://www.cancergenetics.com/
Phone: (201) 528-9200
Email: contact@cancergenetics.com

Super Tiny float: 27M shares in which only a few millions shares available for trading!

Super Tiny OS: 38M shares.

Restricted: 11,453,751 shares.

Tiny AS: 70M shares.

Asset Value: $0.361 per share.


Cash Value: $0.1805 per share.

Enterprise Value: $0.24 per share.

Analyst's Target: $0.4686 per share.











Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences